MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...

The scan found 91 percent of dangerous tumors and correctly cleared most men who didn’t need a biopsy at all.

Prostate MRI currently lacks the accuracy to replace biopsies in active surveillance for prostate cancer. The negative predictive value of MRI remains below 90%, the general goal for safely avoiding ...

For men with elevated prostate-specific antigen (PSA) levels who are at average risk for prostate cancer, evaluating suspicious lesions with MRI-directed targeted biopsy instead of systematic biopsy ...

GRENOBLE, France and PRINCETON, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS ("Koelis" or the "Company", www.koelis.com), a leader and innovator in MRI-ultrasound fusion guidance for prostate ...

A trial found no meaningful difference in detection of clinically significantly prostate cancer between multiparametric MRI-based and microultrasound-based biopsy techniques.

A prostate biopsy is a procedure to remove small samples of tissue from the prostate gland. It's a method to test for prostate cancer if a prostate-specific antigen (PSA) blood test or digital rectal ...

GRENOBLE, France, March 20, 2025 (GLOBE NEWSWIRE) -- Koelis, SAS ("Koelis" or the "Company", www.koelis.com), a global leader and innovator in urology and prostate care, announced today it is ...